These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
403 related articles for article (PubMed ID: 17457951)
1. Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: a retrospective cohort study. Devine ME; Fonseca JA; Walker RW; Sikdar T; Stevens T; Walker Z Int J Geriatr Psychiatry; 2007 Nov; 22(11):1120-6. PubMed ID: 17457951 [TBL] [Abstract][Full Text] [Related]
2. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle. Pakrasi S; Mukaetova-Ladinska EB; McKeith IG; O'Brien JT Int J Geriatr Psychiatry; 2003 Oct; 18(10):879-86. PubMed ID: 14533120 [TBL] [Abstract][Full Text] [Related]
3. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Verdelho A; Madureira S; Moleiro C; Ferro JM; Santos CO; Erkinjuntti T; Pantoni L; Fazekas F; Visser M; Waldemar G; Wallin A; Hennerici M; Inzitari D; Neurology; 2010 Jul; 75(2):160-7. PubMed ID: 20625169 [TBL] [Abstract][Full Text] [Related]
4. Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease. Connelly PJ; Prentice NP; Fowler KG Int J Geriatr Psychiatry; 2005 Jul; 20(7):623-8. PubMed ID: 16021654 [TBL] [Abstract][Full Text] [Related]
5. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Daiello LA; Ott BR; Lapane KL; Reinert SE; Machan JT; Dore DD Am J Geriatr Pharmacother; 2009 Apr; 7(2):74-83. PubMed ID: 19447360 [TBL] [Abstract][Full Text] [Related]
6. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744 [TBL] [Abstract][Full Text] [Related]
7. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Suh GH; Ju YS; Yeon BK; Shah A Int J Geriatr Psychiatry; 2004 Sep; 19(9):817-24. PubMed ID: 15352138 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and cognitive impact of cerebrovascular findings in Alzheimer's disease: a retrospective, naturalistic study. Tabet N; Quinn R; Klugman A Int J Clin Pract; 2009 Feb; 63(2):338-45. PubMed ID: 19196375 [TBL] [Abstract][Full Text] [Related]
9. Cognitive status correlates with neuropathologic stage in Parkinson disease. Braak H; Rüb U; Jansen Steur EN; Del Tredici K; de Vos RA Neurology; 2005 Apr; 64(8):1404-10. PubMed ID: 15851731 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive geriatric assessment in female elderly patients with Alzheimer disease and other types of dementia. Riccio D; Solinas A; Astara G; Mantovani G Arch Gerontol Geriatr; 2007; 44 Suppl 1():343-53. PubMed ID: 17317473 [TBL] [Abstract][Full Text] [Related]
11. The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Stavitsky K; Brickman AM; Scarmeas N; Torgan RL; Tang MX; Albert M; Brandt J; Blacker D; Stern Y Arch Neurol; 2006 Oct; 63(10):1450-6. PubMed ID: 17030662 [TBL] [Abstract][Full Text] [Related]
12. White matter hyperintensities and cognitive dysfunction in Alzheimer disease. Heo JH; Lee ST; Kon Chu ; Park HJ; Shim JY; Kim M J Geriatr Psychiatry Neurol; 2009 Sep; 22(3):207-12. PubMed ID: 19433863 [TBL] [Abstract][Full Text] [Related]
13. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Bonanni L; Thomas A; Tiraboschi P; Perfetti B; Varanese S; Onofrj M Brain; 2008 Mar; 131(Pt 3):690-705. PubMed ID: 18202105 [TBL] [Abstract][Full Text] [Related]
14. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease. Haywood WM; Mukaetova-Ladinska EB Am J Geriatr Pharmacother; 2006 Sep; 4(3):273-86. PubMed ID: 17062329 [TBL] [Abstract][Full Text] [Related]
15. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Beyer MK; Larsen JP; Aarsland D Neurology; 2007 Aug; 69(8):747-54. PubMed ID: 17709706 [TBL] [Abstract][Full Text] [Related]
16. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. Rockwood K; Dai D; Mitnitski A Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382 [TBL] [Abstract][Full Text] [Related]
17. A possible role of atrial fibrillation as a risk factor for dementia. Ettorre E; Cicerchia M; De Benedetto G; Fossati C; Guglielmi S; Manzon L; Servello A; Petrillo A; Marigliano V Arch Gerontol Geriatr; 2009; 49 Suppl 1():71-6. PubMed ID: 19836618 [TBL] [Abstract][Full Text] [Related]
18. Cerebral white matter lesions in patients with dementia - from MCI to severe Alzheimer's disease. Targosz-Gajniak M; Siuda J; Ochudło S; Opala G J Neurol Sci; 2009 Aug; 283(1-2):79-82. PubMed ID: 19268974 [TBL] [Abstract][Full Text] [Related]
19. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. Lopez OL; Becker JT; Saxton J; Sweet RA; Klunk W; DeKosky ST J Am Geriatr Soc; 2005 Jan; 53(1):83-7. PubMed ID: 15667381 [TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Smith EE; Egorova S; Blacker D; Killiany RJ; Muzikansky A; Dickerson BC; Tanzi RE; Albert MS; Greenberg SM; Guttmann CR Arch Neurol; 2008 Jan; 65(1):94-100. PubMed ID: 18195145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]